Dabigatran as an alternative for atrial thrombosis resistant to rivaroxaban: A case report

Anti-thrombosis therapy for atrial fibrillation (AF) management and stroke prevention is an important aspect of disease management. Novel oral anticoagulants (NOACs) are recommended by guidelines for AF management. However, if one can switch one NOAC to another when the former showed a poor effect h...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2018-12, Vol.97 (51), p.e13623-e13623
Main Authors: Sun, Huan, Zhao, Qini, Wang, Yanjing, Lakin, Robert, Liu, Xueyan, Yu, Ming, Yang, Hongliang, Gao, Dongmei, Chen, Weiwei, Gao, Guangyuan, Yan, Mengjie, He, Yuquan, Yang, Ping
Format: Article
Language:English
Subjects:
Antithrombins - therapeutic use
Atrial Fibrillation - drug therapy
Atrial Fibrillation - etiology
Clinical Case Report
Dabigatran - therapeutic use
Drug Resistance
Heart Atria
Heart Diseases - complications
Heart Diseases - drug therapy
Humans
Male
Middle Aged
Rivaroxaban - therapeutic use
Thrombosis - complications
Thrombosis - drug therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-thrombosis therapy for atrial fibrillation (AF) management and stroke prevention is an important aspect of disease management. Novel oral anticoagulants (NOACs) are recommended by guidelines for AF management. However, if one can switch one NOAC to another when the former showed a poor effect has not been fully determined. A 52-year-old man was admitted to our center for heart failure and AF with a thrombus in the left atrium. Cardiomyopathy was diagnosed by cardiac magnetic resonance (CMR) and echocardiography. He was prescribed rivaroxaban (20 mg daily) as treatment, and dabigatran (150 mg twice daily) was used when the thrombus was found to be non-response to rivaroxaban. The rivaroxaban did not diminish the atrial thrombus, and dabigatran was given instead which finally eliminated the thrombus. Individualized responsiveness to NOACs should be considered and paid more attention to during clinical practice.
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000013623